Description du projet
Une thérapie d’expansion cellulaire ex vivo pour soigner les victimes d’infarctus du myocarde
L’infarctus du myocarde, également connu sous le nom de crise cardiaque, se produit lorsque le cœur ne reçoit pas suffisamment d’oxygène en raison d’une diminution du flux sanguin. Le muscle cardiaque est alors endommagé et, en fonction de la gravité de la lésion, cela peut entraîner une insuffisance cardiaque. Le projet EuroXpand, financé par l’UE, entend améliorer le remodelage du cœur à la suite d’un infarctus, en adoptant une approche de médecine régénérative. L’équipe a développé une approche hématopoïétique autologue basée sur des cellules souches qui améliore la fonction cardiaque après perfusion. Les cellules sont développées ex vivo dans des conditions standardisées, à l’aide d’une plateforme de bioproduction conçue en interne et brevetée, afin de répondre aux critères de qualité et de reproductibilité à moindre coût.
Objectif
Heart failure (HF) after acute myocardial infarction (AMI) remains the first cause of death in developed countries, above cancer, with a life expectancy less than 5 years. With an overall cost of 83 billion euros per year worldwide , HF represents a global public-health issue. Treatments following AMI are still characterised by burdensome surgical procedures and post-operative treatments which both fail to prevent HF development.
In this context, CellProthera, founded in 2008, developed an innovative technology based on the discoveries of its founder, Pr. Hénon, who has worked on stem cells for more than 35 years. Unlike its competitors, CellProthera has already demonstrated the efficacy and the safety of its cell therapy, thanks to a successful Proof of Concept study. The clinical outcomes indicated an excellent safety profile associated with an outstanding long-term recovery of the cardiac function, facilitating socio-professional reinsertion.
The process used during the pilot phase could not be patented nor industrialised, limiting its availability to all patients. Hence, Cellprothera has developed a patented cell expansion automate StemXpand®, combined with StemPack® Kit creating an innovative business model, and a new cell therapy process less invasive, more affordable, and decreasing health costs related to HF in the order of 50 to 75%.
With the efficacy demonstration of the new process through EuroXpand project, Cellprothera’s cell therapy could become the reference treatment to prevent HF after AMI. This way, CellProthera will be in possession of all the assets required to achieve a leader position in HF prevention, after AMI. Indeed, with a potential of millions patients / year worldwide, Cellprothera’s total turnover is expected to reach 2,7 billion euros in 2030, associated to the creation of at least 70 direct jobs by 2027 and several thousands of indirect jobs, particularly in Cell Therapy Centres.
Champ scientifique
- social scienceseconomics and businessbusiness and managementbusiness models
- medical and health sciencesmedical biotechnologycells technologiesstem cells
- medical and health sciencesclinical medicinesurgerysurgical procedures
- medical and health sciencesclinical medicineoncology
- medical and health sciencesclinical medicinecardiology
Programme(s)
Régime de financement
SME-2 - SME instrument phase 2Coordinateur
68100 MULHOUSE
France
L’entreprise s’est définie comme une PME (petite et moyenne entreprise) au moment de la signature de la convention de subvention.